Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug efficacy

Evolocumab shows promising results in familial hypercholesterolaemia

Many patients with familial hypercholesterolaemia (FH) fail to achieve recommended levels of low-density lipoprotein (LDL) cholesterol despite pharmacological therapy.

Evolocumab, a fully human monoclonal antibody to PCSK9 (pictured) reduces low-density lipoprotein (LDL) cholesterol in patients with familial hypercholesterolemia

Source: PDBbot / Wikimedia Commons

Evolocumab is a fully human monoclonal antibody to PCSK9 (pictured)

Two studies in The Lancet (online, 1 October 2014) show that evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL cholesterol significantly more than placebo when added to background lipid-lowering therapy in patients with FH, including those with the rare homozygous form of the disease.

The TESLA Part B study[1] included 49 patients with homozygous FH while RUTHERFORD-2[2] enrolled 331 patients with heterozygous FH. Evolocumab, administered either fortnightly or monthly, yielded rapid reductions in LDL cholesterol and was well tolerated.

Evolocumab has previously demonstrated efficacy in a broad range of statin-treated patients with primary hypercholesterolaemia.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066714

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Evolocumab, a fully human monoclonal antibody to PCSK9 (pictured) reduces low-density lipoprotein (LDL) cholesterol in patients with familial hypercholesterolemia

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.